Search

Displaying results 3191 - 3200 of 6835 in total
  1. Drug

    Nivolumab

    go.drugbank.com/drugs/DB09035
    ApprovedInvestigational

    [A35203] It was developed by Bristol Myers Squibb.[L12129] Nivolumab was granted FDA approval on 22 December 2014.

  2. Drug

    Benzoin

    go.drugbank.com/drugs/DB14020
    ApprovedWithdrawn

    Benzoin is a white crystalline compound prepared by condensation of benzaldehyde in potassium cyanide, and is used in organic syntheses.

  3. Drug

    Biomed 101

    go.drugbank.com/drugs/DB05851
    Investigational

    Biomed 101 binds to the leukotriene B4 receptor, but does not affect interleukin-2 antitumor activity.

  4. Drug

    Sitaxentan

    go.drugbank.com/drugs/DB06268
    ApprovedWithdrawn

    Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008.

  5. Drug

    CX-046684

    go.drugbank.com/drugs/DB19414
    Approved

    CX-046684 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage KP.2. It is the active ingredient of the 2024-2025 formulation of Moderna's Spikevax vaccine.

  6. Drug

    Tianeptine

    go.drugbank.com/drugs/DB09289
    Investigational

    Asia (including Singapore) and Latin America as “Stablon” and “Tatinol” but it is not available in Australia, Canada, New Zealand, the U.K. or the U.S. … Tianeptine was discovered and patented by The French Society of Medical Research in the 1960s [L2946].

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  7. Drug

    Cisplatin

    go.drugbank.com/drugs/DB00515
    ApprovedInvestigational

    Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung

  8. Drug

    Catridecacog

    go.drugbank.com/drugs/DB09310
    Approved

    It is subsequently isolated by homogenization of cells and purification by several chromatography steps, including hydrophobic interaction and ion exchange chromatography [FDA Label]. … In these patients, activated rFXIII has been shown to increase the mechanical strength of fibrin clots, slow down fibrinolysis, and to enhance platelet adhesion to the site of injury.

  9. Drug

    Aceclidine

    go.drugbank.com/drugs/DB13262
    Approved

    , and lens anterior displacement, leading to reduced risk of retina or vitreous tractions. … [A274283] As compared to less selective miotics, like [pilocarpine], aceclidine's relative stimulation of the ciliary muscle is significantly less and, as such, induces far less myopic shift, lens thickening

  10. Drug

    Nilotinib

    go.drugbank.com/drugs/DB04868
    ApprovedInvestigational

    A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec